SEC Form 4 · accession 0001520262-26-000118
Alkermes plc. · ALKS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Craig C. Hopkinson
Officer — EVP R&D, Chief Medical Officer
Period of report
Sep 1, 2026
Accepted (ET)
Sep 1, 2026 · 7:08 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001520262
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Sep 1, 2026 | M | 5,000 | $24.59 | A | 74,389 | D | |
| Ordinary SharesF3 | Sep 1, 2026 | S | 9,000 | $46.986 | D | 65,389 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F4 | $24.59 | Sep 1, 2026 | M | 5,000 | D | — | Feb 18, 2032 | Ordinary Shares | 5,000 | 61,276 | D |
Explanation of responses
- F1This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
- F2This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.8269 to $47.3197. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.
- F4These options are fully vested in accordance with their terms.